BRPI0809112A2 - Formulações estáveis de anticorpos - Google Patents

Formulações estáveis de anticorpos Download PDF

Info

Publication number
BRPI0809112A2
BRPI0809112A2 BRPI0809112-9A BRPI0809112A BRPI0809112A2 BR PI0809112 A2 BRPI0809112 A2 BR PI0809112A2 BR PI0809112 A BRPI0809112 A BR PI0809112A BR PI0809112 A2 BRPI0809112 A2 BR PI0809112A2
Authority
BR
Brazil
Prior art keywords
imc
formulations
formulation
formulation according
liquid formulation
Prior art date
Application number
BRPI0809112-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Arvind Srivastava
Joel Goldstein
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of BRPI0809112A2 publication Critical patent/BRPI0809112A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0809112-9A 2007-03-22 2008-03-20 Formulações estáveis de anticorpos BRPI0809112A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91974407P 2007-03-22 2007-03-22
US60/919,744 2007-03-22
PCT/US2008/057718 WO2008116103A2 (en) 2007-03-22 2008-03-20 Stable antibody formulations

Publications (1)

Publication Number Publication Date
BRPI0809112A2 true BRPI0809112A2 (pt) 2014-08-26

Family

ID=39766776

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809112-9A BRPI0809112A2 (pt) 2007-03-22 2008-03-20 Formulações estáveis de anticorpos

Country Status (18)

Country Link
US (1) US20100260766A1 (https=)
EP (1) EP2136839A4 (https=)
JP (1) JP2010522208A (https=)
KR (1) KR20090113340A (https=)
CN (1) CN101668540A (https=)
AU (1) AU2008228823A1 (https=)
BR (1) BRPI0809112A2 (https=)
CA (1) CA2681743A1 (https=)
CR (1) CR11005A (https=)
DO (1) DOP2009000222A (https=)
EA (1) EA200970880A1 (https=)
EC (1) ECSP099642A (https=)
IL (1) IL200321A0 (https=)
MX (1) MX2009010179A (https=)
TN (1) TN2009000382A1 (https=)
UA (1) UA96473C2 (https=)
WO (1) WO2008116103A2 (https=)
ZA (1) ZA200905636B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
TW200838559A (en) * 2006-11-29 2008-10-01 Imclone Systems Inc Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
NZ592151A (en) 2008-12-12 2012-10-26 Boehringer Ingelheim Int Anti-igf antibodies
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
CA2810731A1 (en) 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph
MX362591B (es) 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EA201992617A1 (ru) * 2011-10-26 2020-03-10 Амген Инк. Способы уменьшения или устранения модификации и разложения белка, обусловленных воздействием уф-излучения
US8609820B2 (en) 2011-10-28 2013-12-17 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
JP2016505601A (ja) 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
SG11201705484WA (en) * 2015-02-09 2017-08-30 Ucb Biopharma Sprl Pharmaceutical formulation
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
JP6992262B2 (ja) * 2016-03-31 2022-02-15 東ソー株式会社 変性抗体測定試薬の製造方法
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN112206320B (zh) * 2019-07-12 2025-02-25 鲁南制药集团股份有限公司 一种cd47单克隆抗体冻干粉制剂及其制备工艺
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PH12012502440A1 (en) * 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2003211990A1 (en) * 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
AU2004212344B2 (en) * 2003-02-13 2009-05-07 Pfizer Products Inc. Uses of anti-insulin-like growth factor I receptor antibodies
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
WO2007110339A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation

Also Published As

Publication number Publication date
IL200321A0 (en) 2010-04-29
CN101668540A (zh) 2010-03-10
AU2008228823A1 (en) 2008-09-25
EP2136839A4 (en) 2010-04-07
US20100260766A1 (en) 2010-10-14
ZA200905636B (en) 2010-10-27
WO2008116103A2 (en) 2008-09-25
ECSP099642A (es) 2009-11-30
CR11005A (es) 2010-08-05
DOP2009000222A (es) 2009-12-15
CA2681743A1 (en) 2008-09-25
JP2010522208A (ja) 2010-07-01
MX2009010179A (es) 2010-03-15
TN2009000382A1 (en) 2010-12-31
EP2136839A2 (en) 2009-12-30
KR20090113340A (ko) 2009-10-29
UA96473C2 (ru) 2011-11-10
WO2008116103A3 (en) 2009-01-08
EA200970880A1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
BRPI0809112A2 (pt) Formulações estáveis de anticorpos
JP7204651B2 (ja) 抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法
JP2022033254A (ja) 抗体製剤および方法
BRPI0707796A2 (pt) formulaÇço, e, mÉtodo de tratamento
CN103108658B (zh) 抗体制剂
CN113316458A (zh) 抗lag3抗体和抗pd-1抗体的共制剂
TW201422235A (zh) 抗－泌乳素受器抗體配方
BR112019020508A2 (pt) anticorpos biespecíficos de ligação a erbb-2 e erbb3 para utilização no tratamento de células que possuem um gene de fusão nrg1
CN101410137A (zh) 抗-igf-1r人单克隆抗体制剂
US20100158919A1 (en) Pharmaceutical Composition
JP2010531306A (ja) 肝細胞増殖因子に対する特異的結合剤の組成物
AU2019276572B2 (en) Phthalocyanine dye conjugate compositions
US20220288208A1 (en) Cetuximab-ir700 conjugate compositions
CA3185960A1 (en) Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine
JP2024526920A (ja) 骨標的療法のための操作された組成物
TW202604966A (zh) 包含結合密連蛋白6及cd3之雙特異性抗體的組合物及其用途
HK40102408B (zh) 含抗lag-3抗体的药物组合物及其用途
HK40102408A (zh) 含抗lag-3抗体的药物组合物及其用途

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.